Abstract

HIDALGO, Isabel et al. Dyslipidemias, fatty liver, and cardiovascular disease. Cardiovasc. metab. sci [online]. 2022, vol.33, n.3, pp.134-139.  Epub May 29, 2023. ISSN 2954-3835.  https://doi.org/10.35366/107628.

Non-alcoholic fatty liver disease (NAFLD) results from an unhealthy lifestyle (including a hypercaloric diet and sedentary lifestyle) and metabolic diseases such as obesity, insulin resistance, dyslipidemia, hypertension, and metabolic syndrome. The accumulation of free fatty acids (FFA) and lipid metabolites in hepatocytes, causes the disturbance of insulin-triggered cell signaling and the development of hepatic insulin resistance, and the consequent development of hyperglycemia and hyperinsulinemia. Also, increased lipogenesis and abnormalities in lipid metabolism trigger atherogenic dyslipidemia with release of adipokines that favor the development and progression of NAFLD. In addition, pro-inflammatory cytokines are released into the circulation, promoting chronic inflammation and thrombotic susceptibility with systemic microvascular damage, leading to cardiovascular disease. This short review addresses the association between NAFLD, metabolic syndrome, and cardiovascular disease.

Keywords : non-alcoholic hepatic steatosis; metabolic syndrome; insulin resistance; obesity; cardiovascular disease.

        · abstract in Spanish     · text in English     · English ( pdf )